Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations

Internal Medicine Journal

Volumn 35, Issue 4, 2005, Pages 206-210

  Kerridge, Ian ^a   Maguire, J ^b   Newby, D ^b   McNeill, P M ^c   Henry, D ^b   Hill, S ^b   Day, R ^d   Macdonald, G ^e   Stokes, B ^b   Henderson, K ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Merck Sharp and Dohme (Australia)   (Australia)

Author keywords

Conflict of interest; Ethics; Influence; Medicine; Pharmaceutical industry

Indexed keywords

ACCREDITATION; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; CONTINUING EDUCATION; DRUG INDUSTRY; HEALTH CARE ORGANIZATION; LIBRARY; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL PROFESSION; MEDICAL RESEARCH; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; TRAVEL; TRUST;

AUSTRALIA; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, MEDICAL; HUMANS; QUESTIONNAIRES; SOCIETIES, MEDICAL;

EID: 20244366398     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2004.00799.x     Document Type: Article

References (17)

1. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ 1993; 149: 1401-7.
2. Silagy C, May F. An Overview of Current Practices of Academic Detailing in Australia and Internationally. Report to Commonwealth Department of Health and Family Services, 1997. Canberra: Australian Government Publishing Service.
3. Roughead EE, Harvey KJ, Gilbert AC. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust NZ J Med 1998; 28: 306-10.
4. Day R. Pharmaceutical company promotion. Striking a balance. Aust NZ J Med 1998; 28: 291-3.
5. Bero L, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med 1992; 327: 1135-40.
6. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement BMJ 2003; 326: 1193-6.
7. Task Force on Financial Conflicts of Interest in Clinical Research. Protecting Subjects, Preserving Trust, Promoting Progress. Washington DC, Washington: Association of American Medical Colleges; 2001; 9.
8. Illich I. Limits to Medicine. London: Penguin; 1990.
9. Cho MK, Shohara R, Schissel A, Rennie D. Policies on faculty conflicts of interest at US universities. JAMA 2000; 284: 2203-8.
10. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539-44.
11. Shortell SM, Waters TM, Clarke KWB, Budetti PB. Physicians as double agents. Maintaining trust in an era of multiple accountabilities. JAMA 1998; 280: 1102-8.
12. Chren M. Independent investigators and for-profit companies. Arch Dermatol 1994; 130: 432-7.
13. Moses H, Braunwald E, Martin JB, Their SO. Collaborating with industry - choices for the academic medical center. N Engl J Med 2002; 347: 1371-5.
14. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R et al. Sponsorship, authorship and accountability. Lancet 2001; 358: 854-6.
15. Smith R. Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003; 326: 1202-5.
16. Gottlieb S. Congress criticizes drugs industry for misleading advertising. BMJ 2002; 325: 137.
17. Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003; 361: 27-32.